Faqja 1 nga 146 rezultatet
ACKNOWLEDGMENT OF FEDERAL RESEARCH SUPPORT
Not applicable.
THE BACKGROUND OF THE INVENTION
The invention relates generally to monoclonal antibodies specific for a neoplasia marker, specifically NADH:protein disulfide reductase, to cell lines producing those neoplastic marker-specific monoclonal
FIELD OF THE INVENTION
This invention relates to the diagnosis and treatment of patients at risk for disorders associated with altered methionine synthase activity.
BACKGROUND OF THE INVENTION
Methionine is an essential amino acid in mammals that is required for protein synthesis. Methionine also
FIELD OF THE INVENTION
The present invention relates to combinations of compounds that can be used in the medicinal field to treat, prophylactically or otherwise, uncontrolled or abnormal proliferation of human tissues. Specifically, the present invention relates to the combination of (I) compounds
BACKGROUND OF THE INVENTION
The invention relates generally to use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in treating cancer. More specifically the invention relates to use of lovastatin and its homologues or analogues to treat human adenocarcinoma and selected
FIELD OF THE INVENTION
This invention relates to the diagnosis and treatment of patients at risk for disorders associated with altered methionine synthase activity.
BACKGROUND OF THE INVENTION
Methionine is an essential amino acid in mammals that is required for protein synthesis. Methionine also
SUMMARY OF INVENTION
The inventors propose a combination of an HMG-CoA reductase inhibitor (also referred to as "HMG-CoA inhibitor(s)"), and COX-2 inhibitor for the treatment of cancer especially prostate cancer and a method of treatment of cancer by that combination, especially prostate cancer. The
FIELD OF THE INVENTION
The present invention pertains to the field of cancer therapeutics and in particular to the use of antisense oligonucleotides alone or in combination with one or more chemotherapeutic drugs for the treatment of cancer.
BACKGROUND
Regulation of ribonucleotide reductase, and
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to certain novel anti-neoplastic, anti-viral and ribonucleotide reductase catalytic activity affecting pharmaceutical compositions and methods of treatment.
2. Prior Art
Due to the critical role played by iron in the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to the killing of neoplastic cells. More specifically, the present invention relates to the use of NADPH cytochrome P450 reductase (RED) to enhance cytochrome P450-based anti-cancer gene therapy.
2. Related
BACKGROUND OF THE INVENTION
The present invention relates to cervical carcinoma cells (HeLa) modified with a nitrate reductase gene fragment.
U.S. Pat. No. 5,003,050, "Diazoluminomelanin and a method for preparing same", issued Mar. 26, 1991 to Kiel et al, describes a polymeric water-soluble
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to certain novel anti-neoplastic, anti-vital and ribonucleotide reductase catalytic activity affecting pharmaceutical compositions and methods of treatment.
2. Prior Art
Due to the critical role played by iron in the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to certain novel anti-neoplastic, anti-vital and ribonucleotide reductase catalytic activity affecting pharmaceutical compositions and methods of treatment.
2. Prior Art
Due to the critical role played by iron in the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to certain novel anti-neoplastic, anti-viral and ribonucleotide reductase catalytic activity affecting pharmaceutical compositions and methods of treatment.
2. Prior Art
Due to the critical role played by iron in the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to certain novel anti-neoplastic, anti-viral and ribonucleotide reductase catalytic activity affecting pharmaceutical compositions and methods of treatment.
2. Prior Art
Due to the critical role played by iron in the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to certain novel anti-neoplastic, anti-vital and ribonucleotide reductase catalytic activity affecting pharmaceutical compositions and methods of treatment.
2. Prior Art
Due to the critical role played by iron in the